Safety and tolerability

Well-tolerated^1-3

PLENVU^® had a comparable safety profile to MOVIPREP^®1

Over 85% of patients treated with PLENVU^® did not experience treatment-related adverse events^1-3

There were no serious treatment-related adverse events with PLENVU^®1-3

The majority of adverse events were mild or moderate^1-3

Changes in laboratory parameters were generally not considered clinically significant^1-3

Has the safety profile expected of a PEG bowel preparation^1,4-6

The only common adverse events associated with PLENVU^® are vomiting, nausea and dehydration⁴

The incidence of treatment-related adverse events was comparable across many patient subgroups, and any differences occurred in subgroups with small or imbalanced patient numbers^7,8

Please refer to the Summary of Product Characteristics for further information on the safety profile of PLENVU^®

Who can you prescribe PLENVU^® for?

Patients with mild-to-moderate renal impairment, hepatic impairment, diabetes, mild cardiac insufficiency, inflammatory bowel disease, or diverticular disease received PLENVU^® during clinical studies^1-3

PLENVU^® can be prescribed without dose adjustments in:⁴

• Elderly patients
• Patients with mild-to-moderate renal impairment
• Patients with mild-to-moderate hepatic impairment